Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 14
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06046222 | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | ||
| NCT04956289 | Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53) | ||
| NCT04687020 | Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) | ||
| NCT03680365 | Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families | ||
| NCT04060199 | Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) | ||
| NCT03167255 | Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) | ||
| NCT00094003 | Study of NS-9 in Patients With Liver Metastases | ||
| NCT05996003 | NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | ||
| NCT02740972 | Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) | ||
| NCT06053814 | NS-050/NCNP-03 in Boys With DMD (Meteor50) | ||
| NCT04337112 | The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation | ||
| NCT04768062 | Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) | ||
| NCT04854096 | Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis | ||
| NCT01423851 | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF |
